Predictors of early treatment discontinuation in a cohort of patients treated with boceprevir-based therapy for hepatitis C infection

Journal of Viral Hepatitis

Volumn 21, Issue 8, 2014, Pages 585-589

  Majid, A ^a,b   McAninch, J ^c   Morgan, D J ^b,c   El Kamary, S S ^c   Zhan, M ^b,c   Kapelusznik, L ^a,b   Talwani, R ^a,b  

^a UNIVERSITY OF MARYLAND   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

adverse events; boceprevir; discontinuation; hepatitis C; treatment

Indexed keywords

BOCEPREVIR; ERYTHROPOIETIN; HEMOGLOBIN; PEGINTERFERON; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; PROLINE;

ADULT; AGED; ANEMIA; ARTICLE; BODY MASS; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EARLY TREATMENT DISCONTINUATION; FATIGUE; FOLLOW UP; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; HYPERTENSION; LIVER CIRRHOSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MENTAL DISEASE; NONHUMAN; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SECONDARY ANALYSIS; SKIN DISEASE; SUBSTANCE ABUSE; TREATMENT DURATION; VETERAN; VIRUS LOAD; WEAKNESS; ANALOGS AND DERIVATIVES; HEPATITIS C, CHRONIC; MIDDLE AGED; PROGNOSIS; TREATMENT WITHDRAWAL;

ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROLINE; RETROSPECTIVE STUDIES; WITHHOLDING TREATMENT;

EID: 84903818715     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12201     Document Type: Article

References (8)

1. Bacon BR, Gordon SC, Lawitz E, et al,. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
2. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
3. Belperio PS, Hwang EW, Thomas IC, et al,. Early virologic responses and hematologic safety of direct-acting antivirals in veterans with chronic hepatitis C. Clin Gastroenterol Hepatol, 2013; 11: 1021-1027.
4. Beste LA, Ioannou GN, Larson MS, et al,. Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication. Clin Gastroenterol Hepatol 2010; 8: 972-978.
5. Jacobson IM, Marcellin P, Zeuzem S, et al,. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peg-interferon/ribavirin. Hepatology 2012; 56: 567-575.
6. Quan H, Li B, Couris CM, et al,. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011; 173: 676-682.
7. Evon DM, Esserman DA, Ramcharran D, et al,. Social support and clinical outcomes during antiviral therapy for chronic hepatitis C. J Psychosom Res 2011; 71: 349-356.
8. Huang C-F, Yag Y-F, Dai H-Y, et al,. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis 2010; 201 (751-759): 11.